HRTX
Heron Therapeutics Inc

7,350
Mkt Cap
$224.36M
Volume
2.16M
52W High
$2.68
52W Low
$0.9999
PE Ratio
-14.71
HRTX Fundamentals
Price
$1.19
Prev Close
$1.20
Open
$1.19
50D MA
$1.30
Beta
1.36
Avg. Volume
1.63M
EPS (Annual)
-$0.1211
P/B
31.06
Rev/Employee
$1.21M
$311.78
Loading...
Loading...
News
all
press releases
Heron Therapeutics (NASDAQ:HRTX) Rating Lowered to Strong Sell at Zacks Research
Zacks Research lowered Heron Therapeutics from a "hold" rating to a "strong sell" rating in a research note on Thursday...
MarketBeat·9h ago
News Placeholder
More News
News Placeholder
What is HC Wainwright's Estimate for HRTX Q1 Earnings?
Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) - Investment analysts at HC Wainwright issued their Q1 2026 EPS estimates for shares of Heron Therapeutics in a research report issued to clients...
MarketBeat·1d ago
News Placeholder
Heron Therapeutics (NASDAQ:HRTX) Issues Earnings Results, Beats Estimates By $0.01 EPS
Heron Therapeutics (NASDAQ:HRTX - Get Free Report) released its quarterly earnings results on Thursday. The biotechnology company reported ($0.02) EPS for the quarter, topping the consensus estimate...
MarketBeat·2d ago
News Placeholder
Heron Therapeutics Q4 Earnings Call Highlights
Heron Therapeutics (NASDAQ:HRTX) reported fourth-quarter and full-year 2025 results while outlining plans to increase commercial investment in 2026 to build on what management described as an...
MarketBeat·2d ago
News Placeholder
Heron Therapeutics (HRTX) Reports Q4 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Heron Therapeutics (HRTX) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Zacks·2d ago
News Placeholder
Earnings Breakdown: Heron Therapeutics Q4
read more...
Benzinga·2d ago
News Placeholder
Heron Therapeutics, Inc. $HRTX Shares Acquired by JW Asset Management LLC
JW Asset Management LLC boosted its stake in Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) by 40.8% in the third quarter, according to its most recent disclosure with the Securities and...
MarketBeat·9d ago
News Placeholder
Heron Therapeutics (HRTX) Expected to Announce Earnings on Thursday
Heron Therapeutics (NASDAQ:HRTX) will be releasing its Q4 2025 earnings before the market opens on Thursday, February 26. (View Earnings Report at...
MarketBeat·9d ago
News Placeholder
Heron Therapeutics, Inc. (NASDAQ:HRTX) Receives Consensus Recommendation of "Hold" from Brokerages
Heron Therapeutics, Inc. (NASDAQ:HRTX - Get Free Report) has received a consensus rating of "Hold" from the five ratings firms that are covering the company, Marketbeat Ratings reports. One equities...
MarketBeat·16d ago
News Placeholder
New York State Common Retirement Fund Buys 816,671 Shares of Heron Therapeutics, Inc. $HRTX
New York State Common Retirement Fund raised its stake in Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) by 46.4% in the 3rd quarter, according to the company in its most recent disclosure with...
MarketBeat·20d ago
<
1
2
...
>

Latest HRTX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.